Supriya Lifescience Ltd - 543434 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022.
We hereby enclose the following: 1. Copy of the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review report issued by Statutory Auditor; Supriya Lifescience Ltd - 543434 - Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Tuesday, February 14, 2023, inter-alia, has: 1. Considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2022. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Wednesday, February 15, 2023 at 11.00 A.M. IST to discuss operational and financial performance of the Company for the quarter and nine months ended December 31, 2022. The invite giving requisite details including the pre-registration link and dial-in details is attached herewith. Supriya Lifescience Ltd - 543434 - Board Meeting Intimation for Considering And Approving Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022.
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022. Supriya Lifescience Ltd - 543434 - Appointment Of Whole Time Director (KMP)
Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at their meeting held on January 23, 2023 have appointed Mr. Manoj Deo Dorlikar as an Additional Director in the capacity of Whole Time Director of the Company w.e.f. January 23, 2023 for a period of three years, subject to approval of the shareholders and the Central Government as may be applicable Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,2015, it is hereby informed that Mr. Balasaheb Sawant, Whole Time Director and Key Managerial Personnel of the Company, has tendered his resignation with effect from January 23, 2023, due to the personal reason. Supriya Lifescience Ltd - 543434 - Appointment Of Chief Financial Officer & Key Managerial Personnel
Appointment of Mr. Krishna Raghunathan as the Chief Financial Officer (KMP) of the Company with effect from January 23, 2023. Mr. Krishna Raghunathan is a dynamic professional with 23+ years of rich experience in financial management. In his last role, Mr. Raghunathan worked for ~5 years as Vice President - Finance, Treasury and Investor Relations with a listed pharmaceuticals Company. Mr. Raghunathan has a demonstrated history of working in diverse industries including pharmaceuticals, packaging and information technology. Mr. Raghunathan is a seasoned pharma specialist with more than 2 decades of experience in companies like Dr. Reddy's Laboratories Limited and Granules India Limited. His appointment is in line with company's strategy to achieve accelerated growth in the years to come. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
With reference to the captioned subject and pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,2015, we wish to inform you that the Board of Directors has approved the following change(s) in Key Managerial Personnel (Chief Financial Officer) of the Company at their meeting held today, i.e. January 23, 2023. Mr. Ashish Nayak has resigned from the position of Chief Financial Officer & KMP of the Company and the Board has accepted his resignation with effect from close of business hours on January 23, 2023, however he will be relieved from the company on January 31, 2023, for smooth transition to his successor. Supriya Lifescience Ltd - 543434 - Rejoinder Of The Article On GST Summons On Certain Companies In The Economic Times Dated Friday, January 13, 2023
This is in reference to the article on GST summons on certain Companies in The Economic Times Friday, 13th January 2023. This article talks about the summons being issued to various companies including Supriya Lifescience Ltd. Supriya Lifescience Ltd - 543434 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a duly signed revised Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company for the quarter ended December 31, 2022.